24 June 2024
24 June 2024
Both Novo Nordisk and Eli Lilly have filed lawsuits against unapproved sellers of their diabetes and weight loss drugs.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
Trial investigators anticipate that the FDA will decide on approval for linvoseltamab in relapsed/refractory multiple myeloma by the end of 2024.
Sarepta’s stock rose by over 36% following the positive news of the FDA expanding the gene therapy’s US label.
The company has also raised $130.7m in a private placement.
The FDA's decision is grounded in results from the ADHERE study.
The approval is grounded on the outcomes from a Phase II trial designed to assess the safety and efficacy of EZHARMIA.
The EC granted the approval based on data from the Phase III FRESCO-2 trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
Give your business an edge with our leading industry insights.
